[go: up one dir, main page]

MX9204374A - Anticuerpo recombinante y metodo para su produccion. - Google Patents

Anticuerpo recombinante y metodo para su produccion.

Info

Publication number
MX9204374A
MX9204374A MX9204374A MX9204374A MX9204374A MX 9204374 A MX9204374 A MX 9204374A MX 9204374 A MX9204374 A MX 9204374A MX 9204374 A MX9204374 A MX 9204374A MX 9204374 A MX9204374 A MX 9204374A
Authority
MX
Mexico
Prior art keywords
production
recombinant antibody
recombinant
antibody
Prior art date
Application number
MX9204374A
Other languages
English (en)
Inventor
Ronald A Newman
Nabil Hanna
Ronald W Raab
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of MX9204374A publication Critical patent/MX9204374A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX9204374A 1991-07-25 1992-07-24 Anticuerpo recombinante y metodo para su produccion. MX9204374A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73506491A 1991-07-25 1991-07-25
US85628192A 1992-03-23 1992-03-23
US91229292A 1992-07-10 1992-07-10

Publications (1)

Publication Number Publication Date
MX9204374A true MX9204374A (es) 1993-03-01

Family

ID=27419193

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9204374A MX9204374A (es) 1991-07-25 1992-07-24 Anticuerpo recombinante y metodo para su produccion.

Country Status (4)

Country Link
US (4) US5658570A (es)
IE (1) IE922437A1 (es)
MX (1) MX9204374A (es)
TW (1) TW393489B (es)

Families Citing this family (532)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
DE69027121T3 (de) 1989-08-07 2001-08-30 Peptech Ltd., Dee Why Bindeligande für tumornekrosisfaktor
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69303494T2 (de) * 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US20050260201A1 (en) * 1993-01-29 2005-11-24 Centocor, Inc. Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins
US7592006B1 (en) * 1993-03-05 2009-09-22 Université Catholique de Louvain Composition comprising the LO-CD2a antibody
US20030064070A1 (en) * 1995-05-30 2003-04-03 Centocor, Inc. Multiple administrations of anti-TNF antibody
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
EP0831917A2 (en) * 1995-06-07 1998-04-01 Innogenetics N.V. Immunotoxins specific for cd80 and cd86 expressing cells
US20030180290A1 (en) * 1995-06-07 2003-09-25 Idec Pharmaceuticals Corporation Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US7399847B1 (en) * 1996-11-25 2008-07-15 The General Hospital Corporation Nucleic acids encoding artificial P-selectin ligands
US7033589B1 (en) * 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
WO1999027098A2 (en) 1997-11-21 1999-06-03 Genentech, Inc. A-33 related antigens and their pharmacological uses
US7147854B2 (en) * 1997-06-23 2006-12-12 Yes Biotech Laboratories Ltd. Topical treatment of psoriasis using neutralizing antibodies to interleukin-8
US6849258B1 (en) 1997-07-18 2005-02-01 Universite Catholique De Louvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US7316923B1 (en) * 1997-09-26 2008-01-08 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
US6897066B1 (en) * 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
DE19802139C1 (de) * 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
EP0937463A1 (en) * 1998-02-18 1999-08-25 The Procter & Gamble Company Skin care compositions
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
GB9809839D0 (en) * 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6299875B1 (en) * 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
IL139419A0 (en) 1998-06-12 2001-11-25 Genentech Inc Monoclonal antibodies, cross-reactive antibodies and method for producing the same
WO2000000156A2 (en) * 1998-06-26 2000-01-06 Trustees Of Dartmouth College Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
IL140701A0 (en) 1998-07-13 2002-02-10 Univ Texas Cancer treatment methods using antibodies to aminophospholipids
US6406693B1 (en) * 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
AU750414B2 (en) 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
KR101063278B1 (ko) * 1998-08-11 2011-09-07 바이오겐 아이덱 인크. Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제
AU761516B2 (en) * 1998-11-09 2003-06-05 Biogen Inc. Chimeric anti-CD20 antibody treatment of patients receiving BMT or PBSC transplants
EP1131093A4 (en) 1998-11-09 2002-05-02 Idec Pharma Corp TREATMENT OF HEMATOLOGICAL VILTIES ASSOCIATED WITH CIRCULATING TUMOR CELLS USING CHIMERIC ANTI-CD20 ANTIBODIES
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US6150119A (en) * 1999-01-19 2000-11-21 Caliper Technologies Corp. Optimized high-throughput analytical system
DE60045240D1 (de) * 1999-03-02 2010-12-30 Centocor Inc Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma
KR20020027311A (ko) 1999-05-07 2002-04-13 제넨테크, 인크. Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료
SK16522001A3 (sk) 1999-05-14 2002-10-08 Imclone Systems Incorporated Liečivo na inhibíciu rastu refraktérnych nádorov
EP1194167B1 (en) * 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
CN1373672A (zh) * 1999-07-12 2002-10-09 杰南技术公司 应用结合cd20的拮抗剂阻断对外来抗原的免疫应答
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US20050170382A1 (en) * 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
AU1095001A (en) * 1999-10-20 2001-04-30 Genentech Inc. Type i cytokine receptor tccr
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20030185796A1 (en) * 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
BR0110364A (pt) * 2000-04-25 2003-12-30 Idec Pharma Corp Administração intratecal de rituximab para tratamento de linfomas do sistema nervoso central
EP1935431A3 (en) 2000-05-15 2008-08-13 Health Research, Inc. Cancer treatments by using a combination of an antibody against her2 and interleukin-2
JP2004512262A (ja) 2000-06-20 2004-04-22 アイデック　ファーマスーティカルズ　コーポレイション 非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
US20050249735A1 (en) * 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US20060018907A1 (en) * 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US20110195063A1 (en) * 2000-08-07 2011-08-11 Centocor, Inc. Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
US20090081234A1 (en) * 2000-08-07 2009-03-26 George Heavner Anti-tnf antibodies, compositions, methods and uses for treatment of depression and related conditions
JP2004527456A (ja) * 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
US7393532B1 (en) 2000-10-18 2008-07-01 Genentech, Inc. Modulation of T cell differentiation for the treatment of T helper cell mediated diseases
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
NZ527284A (en) 2001-01-31 2007-03-30 Biogen Idec Inc Anti-CD23 antibodies for the immunotherapeutic treatment of malignancies including B cell chronic lymphocytic leukaemia
AU2002243718B2 (en) * 2001-01-31 2007-12-06 Biogen Idec Inc. Use of immunoregulatory antibodies in the treatment of neoplastic disorders
WO2002070668A2 (en) * 2001-03-06 2002-09-12 Sierra Sciences, Inc. Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
US20050176629A1 (en) * 2001-03-13 2005-08-11 Andrews William H. Telomerase expression repressor proteins and methods of using the same
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
JP2005500018A (ja) * 2001-04-02 2005-01-06 アイデック ファーマスーティカルズ コーポレイション ＧｎＴＩＩＩと同時発現する組換え抗体
AU2002345743A1 (en) * 2001-06-21 2003-01-08 Sierra Sciences, Inc. Telomerase expression repressor proteins and methods of using the same
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
EP1425694A2 (en) * 2001-08-03 2004-06-09 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
DE60230918D1 (de) 2001-11-16 2009-03-05 Biogen Idec Inc Polycistronische expression von antikörpern in cho zellen
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
US20090042291A1 (en) * 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
WO2004001007A2 (en) * 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
US7335743B2 (en) 2002-10-16 2008-02-26 Amgen Inc. Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
KR100932340B1 (ko) * 2002-10-17 2009-12-16 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
MXPA05005921A (es) 2002-12-02 2005-10-19 Abgenix Inc Anticuerpos dirigidos a factor de necrosis tumoral y sus usos.
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
EP1596806A4 (en) * 2003-01-27 2007-08-29 Biogen Idec Inc COMPOSITIONS AND METHODS FOR TREATING CANCER USING IGSF9 AND LIV-1
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
ES2537015T3 (es) * 2003-03-19 2015-06-01 Biogen Ma Inc. Proteína de unión del receptor de NOGO
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
EP1613350B1 (en) 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
EP1615956A1 (en) * 2003-04-14 2006-01-18 Board Of Regents The University Of Texas System Methods for ex vivo hybridoma-free production of polyclonal and monoclonal antibodies and generation of immortalized cell populations
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
KR101412271B1 (ko) * 2003-05-09 2014-06-25 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1685236A4 (en) * 2003-09-29 2008-01-23 Univ California METHODS FOR MODIFYING ADHESION, DIFFERENTIATION AND MIGRATION OF HEMATOPOIETIC PROGENITOR CELLS
US20050239700A1 (en) * 2003-10-14 2005-10-27 Biogen Idec Inc. Treatment of cancer using antibodies to LRRC15
US20070098717A1 (en) 2003-11-04 2007-05-03 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
ATE516819T1 (de) 2003-11-04 2011-08-15 Novartis Vaccines & Diagnostic Verfahren zur behandlung von b-zell-bedingtem krebs
US20070110754A1 (en) 2003-11-04 2007-05-17 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
PL1684805T3 (pl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostics Inc Sposoby leczenia szpiczaka mnogiego z zastosowaniem antagonistycznych monoklonalnych przeciwciał przeciwko CD40
KR101403910B1 (ko) 2003-11-04 2014-06-09 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 길항제 항-ｃｄ４０ 단클론성 항체 및 그것의 사용 방법
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP2397189B1 (en) 2003-11-14 2015-03-18 Brigham and Women's Hospital, Inc. Methods of modulating immunity
US20060003412A1 (en) * 2003-12-08 2006-01-05 Xencor, Inc. Protein engineering with analogous contact environments
US20070249809A1 (en) * 2003-12-08 2007-10-25 Xencor, Inc. Protein engineering with analogous contact environments
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
PL1735348T3 (pl) * 2004-03-19 2012-11-30 Imclone Llc Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu
AU2005247303A1 (en) * 2004-04-16 2005-12-08 Genentech, Inc. Treatment of polychondritis and mononeuritis multiplex with anti-CD20 antibodies
ZA200608572B (en) * 2004-04-16 2008-06-25 Genentech Inc Assay for antibodies
EP1740946B1 (en) * 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
TW201422238A (zh) * 2004-06-04 2014-06-16 Genentech Inc Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
DOP2005000108A (es) * 2004-06-04 2007-06-15 Genentech Inc Method for treating lupus
EP1776136B1 (en) 2004-06-24 2012-10-03 Biogen Idec MA Inc. Treatment of conditions involving demyelination
JP2008505174A (ja) 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体
WO2006012508A2 (en) * 2004-07-22 2006-02-02 Genentech, Inc. Method of treating sjögren's syndrome
WO2006017574A1 (en) * 2004-08-03 2006-02-16 Mayo Foundation For Medical Education And Research Improving treatments
CN101010430A (zh) * 2004-08-03 2007-08-01 转化技术制药公司 Rage融合蛋白及使用方法
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
NZ552128A (en) 2004-08-03 2009-09-25 Transtech Pharma Inc Rage fusion proteins without Fc hinge region and methods of use
MX2007001468A (es) 2004-08-06 2007-03-26 Genentech Inc Ensayos y metodos que utilizan biomarcadores.
AU2005271601A1 (en) 2004-08-06 2006-02-16 Genentech, Inc. Assays and methods using biomarkers
US20060063187A1 (en) * 2004-09-15 2006-03-23 Hotamisligil Gokhan S Modulation of XBP-1 activity for treatment of metabolic disorders
CA2580271A1 (en) * 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
EP2325206B1 (en) 2004-11-12 2014-03-19 Xencor, Inc. Fc variants with altered binding to fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1812064A4 (en) 2004-11-19 2009-07-08 Cornell Res Foundation Inc USE OF VASCULAR ENDOTHEL GROWTH FACTOR RECEPTOR 1+ CELLS IN THE TREATMENT AND MONITORING OF CANCER AND SCREENING IN CHEMOTHERAPY
US20060177436A1 (en) * 2004-12-16 2006-08-10 Genentech, Inc. Methods for Treating Autoimmune Disorders
MX2007007165A (es) * 2004-12-17 2007-08-14 Genentech Inc Terapia de antiangiogenesis de enfermedad autoinmune en pacientes en quienes ha fallado la terapia anterior.
KR20070100346A (ko) 2005-01-05 2007-10-10 바이오겐 아이덱 엠에이 인코포레이티드 크립토 결합 분자
KR101335798B1 (ko) 2005-02-15 2013-12-02 듀크 유니버시티 항-ｃｄ19 항체 및 종양학에서 이의 용도
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP1866339B8 (en) 2005-03-25 2021-12-01 GITR, Inc. Gitr binding molecules and uses therefor
AU2006244445B2 (en) 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
WO2006125117A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
US7601335B2 (en) * 2005-05-20 2009-10-13 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
ES2547463T3 (es) * 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
PT1899378E (pt) 2005-06-21 2010-01-26 Xoma Technology Ltd Anticorpos de ligação de il-1β e os seus fragmentos
CA2652434A1 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized proteins that target ep-cam
DK1904104T3 (da) 2005-07-08 2013-11-11 Biogen Idec Inc SP35-antistoffer og anvendelser heraf
BRPI0614475B8 (pt) * 2005-08-03 2021-05-25 Fraunhofer Usa Inc polipeptídeo, anticorpo, ácido nucleico, vetores, célula hospedeira, composição e processos de produção de anticorpo
PT1915626E (pt) 2005-08-16 2012-02-03 Genentech Inc Sensibilidade da apoptose a apo2l/trail por ensaio de expressão de galnac-t14 em células/tecidos
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
AU2006311828B2 (en) 2005-11-04 2013-07-11 Biogen Ma Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2627446A1 (en) * 2005-11-21 2007-05-31 Laboratoires Serono S.A. Compositions and methods of producing hybrid antigen binding molecules and uses thereof
NZ569428A (en) 2005-12-02 2012-11-30 Biogen Idec Inc Treatment of conditions involving demyelination with a Sp35 antagonist
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
EP2526968A3 (en) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo receptor antagonists
US8808698B2 (en) * 2006-02-03 2014-08-19 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
US20090004190A1 (en) * 2006-02-09 2009-01-01 Mjalli Adnan M M Rage Fusion Proteins And Methods Of Use
US20080279877A1 (en) * 2006-02-13 2008-11-13 Fraunhofer U.S.A. Inc. HPV antigens, vaccine compositions, and related methods
US8277816B2 (en) * 2006-02-13 2012-10-02 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
EP2650306A1 (en) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US20080279848A1 (en) * 2006-03-16 2008-11-13 Genentech, Inc. Methods of treating lupus using CD4 antibodies
BRPI0708902A2 (pt) * 2006-03-16 2011-06-14 Genentech Inc mÉtodos de tratar lupus usando anticorpos cd4
EP2420246A1 (en) 2006-04-20 2012-02-22 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods and compositions based on shiga toxin type 1 protein
CN101426817B (zh) 2006-04-21 2013-07-10 诺华有限公司 拮抗性抗-cd40抗体药物组合物
EP2380983A3 (en) 2006-05-05 2012-12-05 TransTech Pharma Inc. RAGE fusion proteins, formulations, and methods of use thereof
TW200813086A (en) * 2006-05-11 2008-03-16 Hoffmann La Roche Immunereconstituted mouse
WO2008094176A2 (en) * 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
US9683026B2 (en) 2006-07-19 2017-06-20 The Trustees Of The University Of Pennslyvania WSX-1/P28 as a target for anti-inflammatory responses
EP2079483A4 (en) * 2006-07-29 2010-10-20 Robert Lamar Bjork Jr BISPECIFIC MONOCLONAL ANTIBODIES (SPECIFIC FOR CD3 AND CD11B) THERAPEUTIC MEDICAMENTS
KR101479537B1 (ko) * 2006-08-03 2015-01-07 백시넥스 인코포레이티드 항-ｉｌ-6 모노클로날 항체 및 이의 용도
AU2007298571B2 (en) 2006-09-22 2012-06-07 St. Jude Children's Research Hospital Modulating regulatory T cell activity via Interleukin 35
SI2457929T1 (sl) 2006-10-04 2016-09-30 Genentech, Inc. ELISA za VEGF
US7695718B2 (en) 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
US20080171344A1 (en) * 2006-12-22 2008-07-17 Kapsner Kenneth P Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
ES2439490T3 (es) 2007-01-05 2014-01-23 University Of Zurich Anticuerpo anti-beta amiloide y usos del mismo
PL2068887T3 (pl) 2007-01-09 2014-09-30 Biogen Ma Inc Przeciwciała przeciw sp35 i ich zastosowanie
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
US7807168B2 (en) * 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
EP2068925A4 (en) 2007-05-07 2011-08-31 Medimmune Llc ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
CA2692933C (en) 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
EP2175884B8 (en) * 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
AU2008282152B2 (en) * 2007-07-31 2013-12-19 Regeneron Pharmaceuticals, Inc. Human antibodies to human CD20 and method of using thereof
US20090038182A1 (en) * 2007-08-09 2009-02-12 Lans Maris J Footwear with built-in scale
CN101820903A (zh) * 2007-08-20 2010-09-01 美国弗劳恩霍夫股份有限公司 预防性和治疗性流感疫苗、抗原、组合物和方法
HRP20141194T1 (hr) * 2007-12-20 2015-04-24 Xoma (Us) Llc Postupci lijeäśenja gihta
KR101616758B1 (ko) 2007-12-26 2016-04-29 젠코어 인코포레이티드 ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
CA2727171A1 (en) * 2008-06-06 2009-12-10 Xoma Technology Ltd. Methods for the treatment of rheumatoid arthritis
AU2009269099B2 (en) * 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
US20100021460A1 (en) * 2008-07-15 2010-01-28 Genentech, Inc. Methods of Treating Autoimmune Diseases Using CD4 Antibodies
WO2010028275A1 (en) 2008-09-05 2010-03-11 Xoma Technology Ltd. METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
BRPI0921845A2 (pt) 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
KR20110101212A (ko) 2008-12-17 2011-09-15 제넨테크, 인크. Ｃ형 간염 바이러스 조합 요법
US20100159485A1 (en) * 2008-12-19 2010-06-24 Centre For Dna Fingerprinting And Diagnostics Detection of mycobacterium tuberculosis
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
AU2009334498A1 (en) 2008-12-31 2011-07-21 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
CA2756186A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
EP2918602A1 (en) 2009-04-16 2015-09-16 AbbVie Biotherapeutics Inc. Anti-TNF-alpha antibodies and their uses
US9034341B2 (en) 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
BRPI1012321A8 (pt) 2009-06-17 2016-09-27 Abbott Biotherapeutics Corp Anticorpos anti-vegf e seus usos
KR101962476B1 (ko) 2009-07-03 2019-03-26 아비펩 피티와이 리미티트 면역성 접합체 및 그 제조방법
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
CN102791735B (zh) 2009-10-16 2016-05-18 瑟维尔实验室 抗前胃泌素的单克隆抗体及其用途
CN102753580A (zh) 2009-10-28 2012-10-24 亚培生物医疗股份有限公司 抗egfr抗体及其用途
SG10201912571XA (en) 2009-11-02 2020-02-27 Univ Washington Therapeutic nuclease compositions and methods
EP2322149A1 (en) 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia
JP2013510871A (ja) 2009-11-12 2013-03-28 ジェネンテック， インコーポレイテッド 樹状突起棘の密度を促す方法
EP2501800A4 (en) 2009-11-17 2013-05-22 Musc Found For Res Dev HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN NUCLEOLIN
US20130183326A9 (en) 2009-11-20 2013-07-18 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
EP2513148B1 (en) 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2 antibodies and their uses
US9315581B2 (en) 2009-12-23 2016-04-19 A Vipep Pty Limited Immuno-conjugates and methods for producing them
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
US9375473B2 (en) 2010-02-19 2016-06-28 Cornell Research Foundation, Inc. Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
EA201201526A1 (ru) 2010-05-07 2013-06-28 Ксома Текнолоджи Лтд. Способы лечения состояний, связанных с il-1b
CA2799915C (en) 2010-05-25 2023-09-26 Genentech, Inc. Methods of purifying polypeptides
US8916152B2 (en) 2010-06-14 2014-12-23 Lykera Biomed Sa S100A4 antibodies and therapeutic uses thereof
WO2011161427A2 (en) 2010-06-25 2011-12-29 Aston University Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
EP2420250A1 (en) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4 antibodies
CA2808154A1 (en) 2010-08-13 2012-02-16 Medimmmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
TR201812636T4 (tr) 2010-10-11 2018-09-21 Biogen Int Neuroscience Gmbh İnsan anti-tau antikorları.
KR20220070586A (ko) 2010-11-08 2022-05-31 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
CN103370333A (zh) 2010-11-10 2013-10-23 埃斯特韦实验室有限公司 高免疫原性hiv p24序列
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
KR102188544B1 (ko) 2010-11-30 2020-12-08 제넨테크, 인크. 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도
US9283271B2 (en) 2010-12-17 2016-03-15 Neurimmune Holding Ag Human anti-SOD1 antibodies
BR112013016235B1 (pt) 2010-12-22 2020-03-31 Cephalon Australia Pty Ltd Anticorpo isolado, uso de um anticorpo, ácido nucleico, célula transformada e composição farmacêutica
EP2665746B1 (en) 2011-01-17 2020-10-28 Lykera Biomed S.A. Antibodies against the s100p protein for the treatment and diagnosis of cancer
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
WO2012100835A1 (en) 2011-01-28 2012-08-02 Laboratorios Del Dr. Esteve, S.A. Methods and compositions for the treatment of aids
WO2012109238A2 (en) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
WO2012142233A1 (en) 2011-04-14 2012-10-18 St. Jude Children's Research Hospital Methods and compositions for detecting and modulating a novel mtor complex
CN103619877B (zh) 2011-04-21 2018-01-02 加文医学研究所 修饰的可变结构域分子及其产生和使用方法b
KR20250037576A (ko) 2011-04-29 2025-03-17 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료적 뉴클레아제 조성물 및 방법
CA2834776A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
US9783594B2 (en) 2011-05-17 2017-10-10 The Rockefeller University Human immunodeficiency virus neutralizing antibodies and methods of use thereof
JP6058645B2 (ja) 2011-06-10 2017-01-11 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）Ｐｓｌ結合分子およびその使用
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
CA2848074A1 (en) 2011-09-09 2013-03-14 Medimmune Limited Anti-siglec-15 antibodies and uses thereof
RU2623122C2 (ru) 2011-10-26 2017-06-22 Новартис Тиргезундхайт АГ Моноклональные антитела и способы их применения
PL3257564T5 (pl) 2011-11-02 2024-10-07 F. Hoffmann-La Roche Ag Chromatografia elucyjna z przeładowaniem
SMT202000542T1 (it) 2011-11-07 2020-11-10 Medimmune Ltd Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
EP2788020A4 (en) 2011-12-05 2015-04-29 Immunomedics Inc THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
WO2013106577A2 (en) 2012-01-10 2013-07-18 Biogen Idec Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
HRP20191920T1 (hr) 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
BR112014018005B1 (pt) 2012-02-15 2021-06-29 F. Hoffmann-La Roche Ag Uso de um complexo não covalente imobilizado
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CN119192402A (zh) 2012-02-15 2024-12-27 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
CA2873623C (en) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
SG11201407512VA (en) 2012-05-18 2014-12-30 Genentech Inc High-concentration monoclonal antibody formulations
US20150353639A1 (en) 2012-05-21 2015-12-10 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
WO2013177187A2 (en) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
EP2863940A4 (en) 2012-06-08 2016-08-10 Biogen Ma Inc Chimeric clotting factors
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
PL2882450T3 (pl) 2012-07-11 2020-06-29 Bioverativ Therapeutics Inc. Kompleks czynnika viii z xten i białkiem czynnika von willebranda oraz jego zastosowania
WO2014018625A1 (en) 2012-07-25 2014-01-30 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
HUE045144T2 (hu) 2012-08-29 2019-12-30 Hoffmann La Roche Véragygát-shuttle
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
NO2760138T3 (es) 2012-10-01 2018-08-04
US9365641B2 (en) 2012-10-01 2016-06-14 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
CN104870014A (zh) 2012-10-09 2015-08-26 比奥根Ma公司 联合治疗及用于治疗脱髓鞘病症的用途
BR112015011011A2 (pt) 2012-11-15 2019-12-17 Genentech Inc cromatografia por troca de íon com gradiente de ph mediada por força iônica
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
BR112015013444B1 (pt) 2012-12-13 2022-11-01 Immunomedics, Inc Uso de um imunoconjugado
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
CA2896066C (en) 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
CN104936980B (zh) 2012-12-31 2019-06-07 生物控股有限公司 用于治疗和预防多瘤病毒相关的疾病的重组人抗体
PL2956477T5 (pl) 2013-02-15 2024-05-27 Bioverativ Therapeutics Inc. Zoptymalizowany gen czynnika viii
RU2015144033A (ru) 2013-03-15 2017-04-26 Эббви Байотекнолоджи Лтд. Антитела против cd25 и их применения
US20140377253A1 (en) 2013-03-15 2014-12-25 Abbvie Biotherapeutics Inc. Fc variants
MX2015012551A (es) 2013-03-15 2016-10-26 Abbvie Biotechnology Ltd Anticuerpos anti-cd25 y sus usos.
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
WO2014167030A1 (en) 2013-04-09 2014-10-16 Acondicionamiento Tarrasense Anti-s100a7 antibodies for the treatment and diagnosis of cancer
PH12021550015A1 (en) 2013-05-20 2022-05-11 Genentech Inc Anti-transferrin receptor antibodies and methods of use
RU2016104542A (ru) 2013-07-12 2017-08-17 Дженентек, Инк. Осуществление оптимизации входных условий ионообменной хроматографии
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
WO2015035180A1 (en) 2013-09-05 2015-03-12 Genentech, Inc. Method for chromatography reuse
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
NZ756750A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
DK3049521T3 (en) 2013-09-25 2019-04-23 Univ Cornell Compounds for inducing antitumor immunity and methods thereof
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
CN105722509A (zh) 2013-10-09 2016-06-29 迈阿密大学 作为感染性疾病和肠道炎症的药物靶标的穿孔蛋白-2活化剂和抑制剂
JP6317440B2 (ja) 2013-10-29 2018-04-25 プレジデント アンド フェローズ オブ ハーバード カレッジ 酸化ストレスを阻害するための方法および組成物
WO2015066550A1 (en) 2013-10-31 2015-05-07 Resolve Therapeutics, Llc Therapeutic nuclease-albumin fusions and methods
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
EP2876114A1 (en) 2013-11-25 2015-05-27 Consejo Superior De Investigaciones Científicas Antibodies against CCR9 and applications thereof
FI4176894T3 (fi) 2014-01-10 2024-05-29 Bioverativ Therapeutics Inc Kimeerisiä tekijä viii -proteiineja ja niiden käyttötarkoituksia
EP3110445A4 (en) 2014-02-25 2017-09-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
RU2688349C2 (ru) 2014-03-21 2019-05-21 Ф. Хоффманн-Ля Рош Аг In vitro прогнозирование времени полужизни антител in vivo
TW202132337A (zh) 2014-05-28 2021-09-01 美商艾吉納斯公司 抗糖皮質素誘導性ｔｎｆｒ家族相關性受體（ｇｉｔｒ）抗體類及使用彼等之方法
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
EP3174898A2 (en) 2014-07-29 2017-06-07 Neurimmune Holding AG Human-derived anti-huntingtin (htt) antibodies and uses thereof
US20170224777A1 (en) 2014-08-12 2017-08-10 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
CN108064248B (zh) 2014-09-30 2022-03-15 生物控股有限公司 人源抗二肽重复(dpr)抗体
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
US10011657B2 (en) 2014-10-31 2018-07-03 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
JP2018500882A (ja) 2014-11-10 2018-01-18 ジェネンテック， インコーポレイテッド 腎症の動物モデルおよびそれを治療するための薬剤
EP3699198B1 (en) 2014-11-17 2025-03-26 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
CN107001473B (zh) 2014-11-19 2021-07-09 豪夫迈·罗氏有限公司 抗-运铁蛋白受体抗体及使用方法
MX2017007629A (es) 2014-12-09 2018-05-17 Abbvie Inc Compuestos inhibidores de bcl-xl que tienen una baja permeabilidad en las celulas y conjugados de anticuerpo-farmaco que los incluyen.
WO2016094505A1 (en) 2014-12-09 2016-06-16 Abbvie Inc. Antibody drug conjugates with cell permeable bcl-xl inhibitors
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
GB2557389B (en) 2015-01-14 2020-12-23 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
CN107406493B (zh) 2015-03-06 2021-08-13 康诺贝林伦瑙有限公司 具有改善的半衰期的经修饰的血管性血友病因子
CA2978256A1 (en) 2015-03-06 2016-09-15 Genentech, Inc. Ultrapurified dsba and dsbc and methods of making and using the same
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
EP3280736A1 (en) 2015-04-07 2018-02-14 F. Hoffmann-La Roche AG Antigen binding complex having agonistic activity and methods of use
EP3286224A4 (en) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
TWI716405B (zh) 2015-05-07 2021-01-21 美商艾吉納斯公司 抗ox40抗體及其使用方法
WO2016187068A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
SI3303400T1 (sl) 2015-05-28 2021-01-29 Genentech, Inc. Na celicah osnovan test za detektiranje anti-CD3 homodimerov
AU2016271142A1 (en) 2015-05-29 2017-11-23 Genentech, Inc. PD-L1 promoter methylation in cancer
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
AU2016303474B2 (en) 2015-07-31 2022-06-16 Immunewalk Therapeutics, Inc. Motile sperm domain containing protein 2 and cancer
ES2836684T3 (es) 2015-07-31 2021-06-28 Vascular Biogenics Ltd Proteína 2 que contiene el dominio del esperma móvil e inflamación
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
HK1257072A1 (zh) 2015-10-06 2019-10-11 豪夫迈‧罗氏有限公司 治疗多发性硬化的方法
ES2810755T3 (es) 2015-11-30 2021-03-09 Abbvie Inc Conjugados fármaco-anticuerpo anti-lrrc15 humano y métodos para su uso
CA3006610A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. Anti-hulrrc15 antibody drug conjugates and methods for their use
EP3383430A4 (en) 2015-12-02 2019-12-18 Agenus Inc. ANTIBODIES AND METHOD FOR USE THEREOF
EP3184544A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein v inhibitors for use as coagulants
WO2017132279A1 (en) 2016-01-25 2017-08-03 Genentech, Inc. Methods for assaying t-cell dependent bispecific antibodies
PT3411478T (pt) 2016-02-01 2022-09-13 Bioverativ Therapeutics Inc Genes do fator viii otimizados
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
WO2017139623A1 (en) 2016-02-10 2017-08-17 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
SG11201808041UA (en) 2016-03-17 2018-10-30 Numab Innovation Ag ANTI-TNFa-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
HUE052773T2 (hu) 2016-03-17 2021-05-28 Tillotts Pharma Ag Anti-TNF alfa antitestek és funkcionális fragmenseik
LT3219727T (lt) 2016-03-17 2021-02-10 Tillotts Pharma Ag Anti-tnf alfa antikūnai ir jų funkciniai fragmentai
CN109071649B (zh) 2016-03-17 2021-10-01 努玛创新有限公司 抗TNFα抗体及其功能片段
IL261261B2 (en) 2016-03-17 2024-04-01 Numab Therapeutics AG Antibodies against TNF-ALPHA and their functional fragments
AU2017257254B2 (en) 2016-04-27 2022-02-24 Immunomedics, Inc. Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
WO2017201036A1 (en) 2016-05-17 2017-11-23 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
MX2018014175A (es) 2016-05-17 2020-02-07 Abbvie Biotherapeutics Inc Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
KR102366355B1 (ko) 2016-05-27 2022-02-24 애브비 바이오테라퓨틱스 인크. 항-cd40 항체 및 이의 용도
US10875921B2 (en) 2016-05-27 2020-12-29 Abbvie Biotherapeutics Inc. Anti-4-1BB antibodies and their uses
IL300274A (en) 2016-06-08 2023-04-01 Abbvie Inc Antibodies against B7–H3 and conjugates of drug and antibody
US10059769B2 (en) 2016-06-13 2018-08-28 I-Mab Anti-PD-L1 antibodies and uses thereof
BR112018075516A2 (pt) 2016-06-17 2019-10-01 Genentech Inc purificação de anticorpos multiespecíficos
US20190241878A1 (en) 2016-07-01 2019-08-08 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
AU2017292752B2 (en) 2016-07-06 2023-07-27 Celgene Corporation Antibodies with low immunogenicity and uses thereof
WO2018013714A1 (en) 2016-07-13 2018-01-18 Biogen Ma Inc. Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
ES3034020T3 (en) 2016-08-15 2025-08-12 Hoffmann La Roche Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
JP7256116B2 (ja) 2016-09-19 2023-04-11 アイ－エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド 抗ｇｍ－ｃｓｆ抗体およびその使用
CN116731197A (zh) 2016-09-19 2023-09-12 豪夫迈·罗氏有限公司 基于补体因子的亲和层析
CA3042989A1 (en) 2016-11-07 2018-05-11 Junho Chung Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
BR112019011198A2 (pt) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc métodos de indução de tolerância imune a fatores de coagulação
US12161696B2 (en) 2016-12-02 2024-12-10 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
CN117586401A (zh) 2017-01-20 2024-02-23 大有华夏生物医药集团有限公司 抗pd-1抗体及其用途
WO2018137598A1 (en) 2017-01-24 2018-08-02 I-Mab Anti-cd73 antibodies and uses thereof
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
CR20190389A (es) 2017-01-31 2019-11-26 Bioverativ Therapeutics Inc Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas
KR20240038148A (ko) 2017-02-07 2024-03-22 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
CA3057841A1 (en) 2017-03-27 2018-10-04 Celgene Corporation Methods and compositions for reduction of immunogenicity
RU2758234C2 (ru) 2017-03-27 2021-10-26 Иммьюномедикс, Инк. ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
CN110352201A (zh) 2017-04-03 2019-10-18 免疫医疗公司 用于癌症疗法的抗体药物缀合物的皮下施用
EP3645563A4 (en) 2017-06-27 2021-03-17 Neuracle Science Co., Ltd ANTI-FAM19A5 ANTIBODIES AND USES THEREOF
EP3645039A4 (en) 2017-06-27 2021-05-05 Neuracle Science Co., Ltd USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS
US11746149B2 (en) 2017-06-27 2023-09-05 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma
AU2018291081B2 (en) 2017-06-27 2025-02-20 Neuracle Science Co., Ltd. Use of anti-FAM19A5 antibodies for treating cancers
WO2019032898A1 (en) 2017-08-09 2019-02-14 Bioverativ Therapeutics Inc. NUCLEIC ACID MOLECULES AND USES THEREOF
US11485781B2 (en) 2017-08-17 2022-11-01 Massachusetts Institute Of Technology Multiple specificity binders of CXC chemokines
CA3073537A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc Soluble interferon receptors and uses thereof
KR20240138135A (ko) 2017-08-25 2024-09-20 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 그의 사용 방법
EP3692171A4 (en) 2017-10-02 2021-06-23 Neuracle Science Co., Ltd USING ANTI-FAMILY WITH SEQUENCE LIKE 19, ELEMENT A5 ANTIBODIES FOR TREATMENT AND DIAGNOSIS OF MENTAL DISORDERS
JP7542257B2 (ja) 2018-01-25 2024-08-30 エイシーエム バイオラブズ プライベート リミテッド 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法
JP2021512126A (ja) 2018-02-01 2021-05-13 バイオベラティブ セラピューティクス インコーポレイテッド 第ｖｉｉｉ因子を発現するレンチウイルスベクターの使用
KR20200123170A (ko) 2018-02-21 2020-10-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 제형
MA52416A (fr) 2018-03-02 2021-04-21 Five Prime Therapeutics Inc Anticorps b7-h4 et leurs procédés d'utilisation
CN119607195A (zh) 2018-04-24 2025-03-14 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
BR112020021855A2 (pt) 2018-04-27 2021-02-23 Biogen Ma Inc. anticorpo antirrepetição de dipeptídeo (dpr) (poli-ga) derivado de humanos
EP3790979A4 (en) 2018-05-08 2022-04-27 Neuracle Science Co., Ltd RELEASE OF ADENO-ASSOCIATED VIRUS (AAV) FROM ANTI-FAM19A5 ANTIBODIES
US11970532B2 (en) 2018-05-10 2024-04-30 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
CN119080931A (zh) 2018-06-04 2024-12-06 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
US11241417B2 (en) 2018-06-21 2022-02-08 Yumanity Therapeutics, Inc. Compositions and methods for the treatment and prevention of neurological disorders
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
CN112601517A (zh) 2018-07-03 2021-04-02 百时美施贵宝公司 Fgf-21配制品
US20220275043A1 (en) 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
CN112424231B (zh) 2018-07-19 2022-09-13 大有华夏生物医药集团有限公司 抗pd-1抗体及其剂量和用途
SG11202101157VA (en) 2018-08-09 2021-03-30 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof for non-viral gene therapy
EP3833693A4 (en) 2018-08-21 2023-06-07 ABL Bio Inc. Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
DK3844189T3 (da) 2018-08-31 2025-02-24 Regeneron Pharma Doseringsstrategi, der mindsker cytokinfrigivelsessyndrom for CD3/CD20-bispecifikke antistoffer
CN112996539A (zh) 2018-09-12 2021-06-18 Acm生物实验室私人有限公司 包含共价结合的抗原的聚合物囊泡以及其制备方法和用途
JP2022513328A (ja) 2018-09-27 2022-02-07 フォスフォガム， インコーポレイテッド 同種異系のガンマ／デルタｔ細胞の増殖および使用のための方法および組成物
EP3856763A1 (en) 2018-09-28 2021-08-04 Massachusetts Institute of Technology Collagen-localized immunomodulatory molecules and methods thereof
JP7211610B2 (ja) 2018-10-16 2023-01-24 ニューラクル サイエンス カンパニー リミテッド 抗ｆａｍ１９ａ５抗体の用途
CN112930350A (zh) 2018-10-31 2021-06-08 尹图赛利有限公司 稠合杂环苯并二氮杂䓬衍生物及其用途
MY206649A (en) 2018-11-30 2024-12-30 I Mab Biopharma Us Ltd Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
TW202035442A (zh) 2018-12-20 2020-10-01 美商建南德克公司 經修飾之抗體Fc及其使用方法
CN113227139B (zh) 2018-12-27 2024-10-29 纽洛可科学有限公司 抗fam19a5抗体治疗动脉粥样硬化的用途
KR102656738B1 (ko) 2019-01-02 2024-04-16 주식회사 뉴라클사이언스 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체 및 이의 사용 방법
KR20210126078A (ko) 2019-02-13 2021-10-19 더 브리검 앤드 우먼즈 하스피털, 인크. 항-말초 림프절 어드레신 항체 및 그의 용도
EP3928790A4 (en) 2019-02-22 2023-01-11 Wuhan Yzy Biopharma Co., Ltd. Cd3 antigen binding fragment and application thereof
CN112142847B (zh) 2019-02-22 2023-05-05 武汉友芝友生物制药股份有限公司 改造的Fc片段，包含其的抗体及其应用
WO2020214963A1 (en) 2019-04-18 2020-10-22 Genentech, Inc. Antibody potency assay
KR20220012883A (ko) 2019-05-23 2022-02-04 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
TWI870412B (zh) 2019-06-05 2025-01-21 美商建南德克公司 過載層析管柱之再生方法
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
CN112513097B (zh) 2019-07-11 2021-10-29 武汉友芝友生物制药有限公司 四价对称双特异性抗体
CN114206929B (zh) 2019-09-03 2023-12-22 百奥泰生物制药股份有限公司 一种抗tigit免疫抑制剂及应用
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
WO2021067389A1 (en) 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Lentiviral vector formulations
CN116249547B (zh) 2019-11-04 2025-11-14 代码生物疗法公司 脑特异性血管生成抑制剂1(bai1)抗体及其用途
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
AU2021215935A1 (en) 2020-02-05 2022-08-25 Diadem Biotherapeutics Inc. Artificial synapses
IL295188A (en) 2020-02-18 2022-09-01 Alector Llc Pilra antibodies and methods of use thereof
IL295980A (en) 2020-02-28 2022-10-01 Brigham & Womens Hospital Inc Selective modulation of transforming growth factor beta superfamily signaling via multi-specific antibodies
WO2021178896A1 (en) 2020-03-06 2021-09-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
WO2021194861A1 (en) 2020-03-23 2021-09-30 Genentech, Inc. Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia
US20230174656A1 (en) 2020-03-23 2023-06-08 Genentech, Inc. Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
EP4107184A1 (en) 2020-03-23 2022-12-28 Genentech, Inc. Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist
HRP20240182T1 (hr) 2020-03-26 2024-04-26 Vanderbilt University Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
CN115362171A (zh) 2020-03-31 2022-11-18 百奥泰生物制药股份有限公司 用于治疗冠状病毒的抗体、融合蛋白及其应用
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CA3182150A1 (en) 2020-05-17 2021-11-25 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of selecting and using the same
BR112022023489A2 (pt) 2020-05-21 2023-03-14 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
BR112022024472A2 (pt) 2020-06-01 2022-12-27 Genentech Inc Métodos para produzir um anticorpo, para detectar um anticorpo em uma amostra, para classificar células produtoras de anticorpos e para produzir uma pluralidade de vesículas, métodos de produção de um anticorpo e de tratamento de um indivíduo com uma doença, anticorpos isolados, ácido nucleico isolado, célula hospedeira, composição farmacêutica, uso do anticorpo isolado e kit
US12173307B2 (en) 2020-06-24 2024-12-24 Bioverativ Therapeutics Inc. Methods for the purification of viral vectors
CN116507636A (zh) 2020-07-20 2023-07-28 阿斯利康(英国)有限公司 SARS-CoV-2蛋白、抗SARS-CoV-2抗体以及它们的使用方法
JP2023537022A (ja) 2020-08-07 2023-08-30 バイオ－テラ ソリュ－ションズ，エルティーディー． 抗ｐｄ－ｌ１抗体及びその応用
CN116234577A (zh) 2020-08-10 2023-06-06 阿斯利康(英国)有限公司 用于治疗和预防covid-19的sars-cov-2抗体
EP4454659A3 (en) 2020-08-18 2025-01-22 Cephalon LLC Anti-par-2 antibodies and methods of use thereof
CN116685351A (zh) 2020-09-17 2023-09-01 基因泰克公司 Empacta的结果：一项用于评估托珠单抗在患有covid-19肺炎的住院患者中的功效和安全性的随机、双盲、安慰剂对照、多中心研究
EP4214244A1 (en) 2020-09-21 2023-07-26 Genentech, Inc. Purification of multispecific antibodies
US20240043528A1 (en) 2020-10-05 2024-02-08 President And Fellows Of Harvard College Nanobody-oga fusions and uses thereof
EP4242232A4 (en) 2020-11-06 2024-09-11 Bio-Thera Solutions, Ltd. BISPECIFIC ANTIBODY AND ITS USE
US11873333B2 (en) 2020-12-11 2024-01-16 The University Of North Carolina At Chapel Hill Compositions and methods comprising SFRP2 antagonists
US20240092892A1 (en) 2020-12-30 2024-03-21 Bio-Thera Solutions, Ltd. Anti-cldn18.2 antibody, and preparation method therefor and use thereof
IL304048A (en) 2020-12-31 2023-08-01 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating myotonic dystrophy
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
US20250326855A1 (en) 2021-03-05 2025-10-23 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
MX2023011371A (es) 2021-03-31 2023-10-06 Hoffmann La Roche Purificacion de anticuerpos mediante cromatografia de modo mezclado.
JP2024518710A (ja) 2021-04-12 2024-05-02 エイシーエム バイオラブズ プライベート リミテッド 可溶性封入ポリヌクレオチドとイオン化可能脂質とを含むポリマーソームならびにその作製および使用方法
MX2023012974A (es) 2021-05-04 2023-11-15 Regeneron Pharma Agonistas multiespecificos de receptores del fgf21 y sus usos.
EP4352101A1 (en) 2021-06-11 2024-04-17 Genentech, Inc. Method for treating chronic obstructive pulmonary disease with an st2 antagonist
KR20240107093A (ko) 2021-08-05 2024-07-08 고 테라퓨틱스, 인크. 항-글리코-muc4 항체 및 그의 용도
CN117881696A (zh) 2021-08-23 2024-04-12 比奥维拉迪维治疗股份有限公司 具有反向末端重复序列的封闭末端dna产生
AR126846A1 (es) 2021-08-23 2023-11-22 Bioverativ Therapeutics Inc Genes del factor viii optimizados
TW202328188A (zh) 2021-09-03 2023-07-16 美商Ｇｏ治療公司 抗醣化-cmet抗體及其用途
AU2022339819A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
EP4408874A1 (en) 2021-09-30 2024-08-07 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
EP4410839A4 (en) 2021-09-30 2025-10-08 Bio Thera Solutions Ltd ANTI-B7-H3 ANTIBODY AND ITS USE
EP4408478A1 (en) 2021-09-30 2024-08-07 Seagen Inc. B7-h4 antibody-drug conjugates for the treatment of cancer
IL311963A (en) 2021-10-15 2024-06-01 Regenxbio Inc Antibodies and methods of using them
MX2024005337A (es) 2021-11-02 2024-07-29 Visterra Inc Variantes de fc con unión suprimida a fcgammar y c1q.
TW202342095A (zh) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防ｃｏｖｉｄ—１９之組成物
AU2022394462A1 (en) 2021-11-17 2024-05-02 AbbVie Deutschland GmbH & Co. KG Methods for treating anemia of kidney disease
EP4433084A1 (en) 2021-11-19 2024-09-25 Lykera Biomed, S.A. Treatment and diagnosis of diseases associated to pathogenic fibrosis
EP4452281A1 (en) 2021-12-22 2024-10-30 Sapreme Technologies B.V. Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders
US20250082759A1 (en) 2021-12-22 2025-03-13 Sapreme Technologies B.V. Compositions comprising therapeutic nucleic acid and targeted saponin for the treatment of muscle-wasting disorders
IL313728A (en) 2021-12-22 2024-08-01 Sapreme Tech Bv Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
JP2025508798A (ja) 2022-02-23 2025-04-10 エイシーエム バイオラブズ プライベート リミテッド 脂質とブロックコポリマーとを含むポリマー－脂質ハイブリッドナノ粒子ならびにその作製方法および使用方法
CA3251490A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Hydroxypropylmethylcellulose derivatives for stabilizing polypeptides
CA3256096A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited ANTIBODIES AGAINST SARS-CoV-2 AND THEIR METHODS OF USE
WO2023209687A1 (en) 2022-04-29 2023-11-02 Crispr Therapeutics Ag Cas9 antibodies and uses thereof
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023232080A1 (zh) 2022-06-01 2023-12-07 百奥泰生物制药股份有限公司 抗cldn18.2抗体及其抗体药物偶联物和用途
AU2023316021A1 (en) 2022-07-29 2025-03-06 Alector Llc Cd98hc antigen-binding domains and uses therefor
CN119497721A (zh) 2022-07-29 2025-02-21 艾莱克特有限责任公司 转铁蛋白受体抗原结合结构域及其用途
EP4331610A1 (en) 2022-09-01 2024-03-06 Sapreme Technologies B.V. Polyplex-saponin covalent conjugate
WO2024046622A1 (en) 2022-09-01 2024-03-07 Sapreme Technologies B.V. Compositions of polyplexes and saponins
EP4331609A1 (en) 2022-09-01 2024-03-06 Sapreme Technologies B.V. Methods and compositions for enhanced polyplex delivery
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024108178A1 (en) 2022-11-18 2024-05-23 Genentech, Inc. Signal amplification and multiplexing using mass tags for ia-lc-ms/ms based assays
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
CN120530134A (zh) 2022-12-22 2025-08-22 朱利叶斯-马克西米利维尔茨堡大学 用作凝血剂的抗体
WO2024150074A2 (en) 2023-01-13 2024-07-18 Takeda Pharmaceutical Company Limited Coronavirus antibodies and therapeutic uses thereof
EP4649092A1 (en) 2023-01-13 2025-11-19 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2024167898A1 (en) 2023-02-07 2024-08-15 Go Therapeutics, Inc. ANTIBODY FUSION PROTEINS COMPRISING ANTI-GLYCO-MUC4 ANTIBODIES AND MIC PROTEIN α1-α2 DOMAINS, AND THEIR USES
IL322995A (en) 2023-03-02 2025-10-01 Alloy Therapeutics Inc Anti-CD22 antibodies and their uses
WO2024206329A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
WO2024246051A1 (en) 2023-06-02 2024-12-05 Sapreme Technologies B.V. Improved treatment regimens for therapeutic effector components that act via an intracellular molecular target
WO2024261042A1 (en) 2023-06-21 2024-12-26 Sapreme Technologies B.V. Conjugates of saponin and antisense oligonucleotides for use in the treatment of neurodegenerative diseases
WO2024261044A1 (en) 2023-06-21 2024-12-26 Sapreme Technologies B.V. Pharmaceutical compositions for treatment of central nervous system disorders
WO2025021790A2 (en) 2023-07-24 2025-01-30 F. Hoffmann-La Roche Ag Multispecific antibodies
TW202515919A (zh) 2023-09-01 2025-04-16 比利時商艾托斯比利時公司 抗ｔｒｅｍ２抗體及使用方法
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
WO2025076389A1 (en) 2023-10-06 2025-04-10 Seagen Inc. Methods of treating advanced solid tumors with b7-h4 antibody-drug conjugates
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants
TW202528347A (zh) 2023-11-15 2025-07-16 瑞士商紐立慕公司 抗運甲狀腺素蛋白抗體、包含所述抗體之組成物及用於治療或預防運甲狀腺素蛋白介導之澱粉樣變性的方法
WO2025166040A1 (en) 2024-01-31 2025-08-07 Alector Llc Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
WO2025166042A1 (en) 2024-01-31 2025-08-07 Alector Llc Cd98hc antigen-binding domains and uses therefor
US20250361297A1 (en) 2024-03-12 2025-11-27 Adaptam Therapeutics, S.L. Anti- siglec-15 binding molecules and methods of use
WO2025233867A1 (en) 2024-05-10 2025-11-13 Adaptam Therapeutics, S.L. Anti-siglec-9 antibodies and uses thereof
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4975369A (en) * 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
DE3814887C1 (es) * 1988-05-02 1989-09-21 Medice Chem.-Pharm. Fabrik Puetter Gmbh & Co Kg, 5860 Iserlohn, De
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
AU4964290A (en) * 1989-01-18 1990-08-13 President And Fellows Of Harvard College Compositions and methods for treating or preventing aids, arc and hiv infection
JP3502093B2 (ja) * 1991-07-15 2004-03-02 ザ・ウエルカム・ファウンデーション・リミテッド 抗体の製造

Also Published As

Publication number Publication date
US5681722A (en) 1997-10-28
IE922437A1 (en) 1993-01-27
TW393489B (en) 2000-06-11
US5693780A (en) 1997-12-02
US5750105A (en) 1998-05-12
US5658570A (en) 1997-08-19

Similar Documents

Publication Publication Date Title
MX9204374A (es) Anticuerpo recombinante y metodo para su produccion.
MX9201355A (es) Bis-naftal imidas y metodo para su preparacion.
FI940144A7 (fi) Vasta-aineiden tuotanto
MX9206628A (es) Ester de prolinaboronato y metodo para su preparacion.
MX9206850A (es) Bloque de material fibroso unido y proceso para su preparacion.
DE68914244D1 (de) Monoklonaler Antikörper.
MX9205315A (es) Arbol de levas y metodo para su produccion
MX9207326A (es) Metodo y aparato para reensayo dirigido avanzado.
MX9201855A (es) Calibrador para frenos y metodo para su fabricacion.
MX9204920A (es) Cianofenilpirroles y procedimiento para su obtencion.
BR9200697A (pt) Oxido de zirconio monoclino,processo para sua preparacao e sua aplicacao
MX9201780A (es) Eteres oximicos y procedimiento para su preparacion.
MX9204769A (es) Material compuesto para empaquetaduras y proceso para su fabricacion.
NO911008D0 (no) For og fremgangsmaate til fremstilling derav.
BR9303670A (pt) Material multicamada, e processo para sua formaçao
MX9205747A (es) Pirazolinas y procedimiento para su preparacion.
MX9102583A (es) Microgranallas para vidriado y procedimiento para su obtencion.
MX9205746A (es) Pirazolinas y procedimiento para su preparacion.
MX9205821A (es) Pirimidinil- y triazinileteres y -tioeteres y procedimiento para su preparacion.
MX9202536A (es) Antibioticos tetraciclicos y procedimiento para su preparacion.
MX9204626A (es) Mensula de soporte y metodo para su fabricacion.
BR9207098A (pt) Painel estrutural método e mecanismo para sua produção
MX9202327A (es) 2-aril pirroles substituidos y procedimiento para su obtencion.
DE68910956D1 (de) Mit toxin modifizierter antikörper.
MX9205257A (es) Dihidropiridinas substituidas por indolsulfonamida y procedimiento para su fabricacion.